Long-term safety data for Revolade in adults with chronic ITP
Data from the largest study of its kind confirm the long-term safety profile of Novartis’ Revolade (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenia (ITP).
Click on this link for more information.
